- Home
- MYGN vs PAX Comparison
MYGN vs PAX Comparison
Compare MYGN & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PAX
- Stock Information
- Founded
- MYGN 1991
- PAX 1988
- Country
- MYGN United States
- PAX Cayman Islands
- Employees
- MYGN N/A
- PAX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PAX Investment Managers
- Sector
- MYGN Health Care
- PAX Finance
- Exchange
- MYGN Nasdaq
- PAX Nasdaq
- Market Cap
- MYGN 2.0B
- PAX 1.8B
- IPO Year
- MYGN 1995
- PAX 2021
- Fundamental
- Price
- MYGN $13.69
- PAX $12.39
- Analyst Decision
- MYGN Hold
- PAX Strong Buy
- Analyst Count
- MYGN 12
- PAX 1
- Target Price
- MYGN $23.92
- PAX $14.00
- AVG Volume (30 Days)
- MYGN 904.0K
- PAX 595.5K
- Earning Date
- MYGN 11-07-2024
- PAX 11-05-2024
- Dividend Yield
- MYGN N/A
- PAX 4.74%
- EPS Growth
- MYGN N/A
- PAX N/A
- EPS
- MYGN N/A
- PAX 0.42
- Revenue
- MYGN $823,600,000.00
- PAX $328,717,000.00
- Revenue This Year
- MYGN $13.82
- PAX $2.35
- Revenue Next Year
- MYGN $4.59
- PAX $26.31
- P/E Ratio
- MYGN N/A
- PAX $30.20
- Revenue Growth
- MYGN 12.15
- PAX 7.39
- 52 Week Low
- MYGN $13.81
- PAX $10.63
- 52 Week High
- MYGN $29.30
- PAX $16.16
- Technical
- Relative Strength Index (RSI)
- MYGN 26.49
- PAX 60.38
- Support Level
- MYGN $13.92
- PAX $12.20
- Resistance Level
- MYGN $15.44
- PAX $12.97
- Average True Range (ATR)
- MYGN 0.79
- PAX 0.29
- MACD
- MYGN 0.03
- PAX 0.02
- Stochastic Oscillator
- MYGN 3.06
- PAX 85.28
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About PAX Patria Investments Limited
Patria Investments Ltd is a private markets investment firm. It seeks to provide global and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns.